Brookfield Asst Financials

BAM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Brookfield Asst (BAM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Brookfield Asst passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

0.88x

For every $1 of reported earnings, Brookfield Asst generates $0.88 in operating cash flow ($2.1B OCF vs $2.4B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.8B

YoY+21.0%

Brookfield Asst generated $4.8B in revenue in fiscal year 2025. This represents an increase of 21.0% from the prior year.

EBITDA

N/A

Net Income

$2.4B

YoY+13.8%

Brookfield Asst reported $2.4B in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.6B

YoY+291.8%

Brookfield Asst held $1.6B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

49.8%

YoY-3.2pp

Brookfield Asst's net profit margin was 49.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.

Return on Equity

26.9%

YoY+2.8pp

Brookfield Asst's ROE was 26.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$412.0M

Brookfield Asst spent $412.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

BAM Income Statement

Metric	FY25	FY24	FY23
Revenue	$4.8B+21.0%	$4.0B-2.0%	$4.1B
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	$56.0M-12.5%	$64.0M+14.3%	$56.0M
Operating Income	N/A	N/A	N/A
Interest Expense	$87.0M+295.5%	$22.0M+144.4%	$9.0M
Income Tax	$527.0M+20.3%	$438.0M+5.0%	$417.0M
Net Income	$2.4B+13.8%	$2.1B-1.4%	$2.1B
EPS (Diluted)	N/A	N/A	$1.13

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.4B+11.3%	$1.3B+14.9%	$1.1B+0.8%	$1.1B+1.7%	$1.1B-4.8%	$1.1B+21.9%	$916.0M+3.6%	$884.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$9.0M-60.9%	$23.0M+27.8%	$18.0M+200.0%	$6.0M-72.7%	$22.0M+10.0%	$20.0M+53.8%	$13.0M+44.4%	$9.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$33.0M+65.0%	$20.0M-35.5%	$31.0M+933.3%	$3.0M-57.1%	$7.0M-12.5%	$8.0M+166.7%	$3.0M-25.0%	$4.0M
Income Tax	$299.0M+283.3%	$78.0M+4.0%	$75.0M0.0%	$75.0M-41.9%	$129.0M+34.4%	$96.0M-32.4%	$142.0M+100.0%	$71.0M
Net Income	$615.0M-11.1%	$692.0M+18.5%	$584.0M+15.2%	$507.0M-25.4%	$680.0M+26.6%	$537.0M+3.7%	$518.0M+38.9%	$373.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BAM Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$17.0B+20.4%	$14.2B+341.7%	$3.2B
Current Assets	N/A	N/A	N/A
Cash & Equivalents	$1.6B+291.8%	$404.0M+4388.9%	$9.0M
Inventory	N/A	N/A	N/A
Accounts Receivable	$106.0M-52.9%	$225.0M	N/A
Goodwill	$236.0M-6.0%	$251.0M	N/A
Total Liabilities	$6.7B+127.1%	$3.0B+164.8%	$1.1B
Current Liabilities	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A
Total Equity	$8.9B+1.8%	$8.8B+321.6%	$2.1B
Retained Earnings	-$851.0M-74.4%	-$488.0M-1294.3%	-$35.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$17.0B+3.2%	$16.5B+2.3%	$16.1B+7.9%	$15.0B+5.7%	$14.2B	N/A	$4.2B	N/A
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$1.6B+49.1%	$1.1B+121.2%	$480.0M+44.6%	$332.0M-17.8%	$404.0M-55.3%	$903.0M+8930.0%	$10.0M-99.6%	$2.6B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$106.0M	N/A	N/A	N/A	$225.0M	N/A	N/A	N/A
Goodwill	$236.0M	N/A	N/A	N/A	$251.0M	N/A	N/A	N/A
Total Liabilities	$6.7B+15.2%	$5.8B+14.4%	$5.1B+25.5%	$4.1B+37.3%	$3.0B	N/A	$925.0M	N/A
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.9B+5.3%	$8.5B-0.1%	$8.5B-0.2%	$8.5B-3.0%	$8.8B-2.8%	$9.0B+178.8%	$3.2B-64.2%	$9.0B
Retained Earnings	-$851.0M-20.9%	-$704.0M+1.5%	-$715.0M-15.9%	-$617.0M-26.4%	-$488.0M	N/A	-$119.0M	N/A

BAM Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	$2.1B+30.3%	$1.6B+12.0%	$1.4B
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$339.0M+80.6%	-$1.7B-267.2%	-$475.0M
Financing Cash Flow	-$590.0M+72.2%	-$2.1B-15.0%	-$1.8B
Dividends Paid	$2.8B+13.7%	$2.5B+17.9%	$2.1B
Share Buybacks	$412.0M	$0-100.0%	$319.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$706.0M-5.2%	$745.0M+40.8%	$529.0M+99.6%	$265.0M+94.9%	$136.0M-76.0%	$567.0M+44.3%	$393.0M-23.8%	$516.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$76.0M-850.0%	-$8.0M+98.4%	-$490.0M-683.3%	$84.0M+127.0%	$37.0M+102.8%	-$1.3B-192.7%	-$452.0M-7433.3%	-$6.0M
Financing Cash Flow	-$108.0M+32.9%	-$161.0M-249.1%	$108.0M+125.6%	-$422.0M+36.0%	-$659.0M-137.9%	-$277.0M+54.1%	-$603.0M-4.0%	-$580.0M
Dividends Paid	$703.0M-0.4%	$706.0M+0.6%	$702.0M-0.7%	$707.0M+14.2%	$619.0M-0.2%	$620.0M+0.2%	$619.0M-0.2%	$620.0M
Share Buybacks	$227.0M+229.0%	$69.0M	$0-100.0%	$116.0M	$0	$0	$0	$0

BAM Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	49.8%-3.2pp	53.0%+0.3pp	52.6%
Return on Equity	26.9%+2.8pp	24.1%-78.9pp	102.9%
Return on Assets	14.1%-0.8pp	14.9%-51.8pp	66.7%
Current Ratio	N/A	N/A	N/A
Debt-to-Equity	0.76+0.4	0.34-0.2	0.54
FCF Margin	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	44.1%-11.1pp	55.3%+1.7pp	53.6%+6.7pp	46.9%-17.1pp	64.0%+15.9pp	48.1%-8.5pp	56.5%+14.4pp	42.2%
Return on Equity	6.9%-1.3pp	8.2%+1.3pp	6.9%+0.9pp	6.0%-1.8pp	7.8%+1.8pp	6.0%-10.1pp	16.0%+11.9pp	4.1%
Return on Assets	3.6%-0.6pp	4.2%+0.6pp	3.6%+0.2pp	3.4%-1.4pp	4.8%	N/A	12.4%	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.76+0.1	0.69+0.1	0.60+0.1	0.48+0.1	0.34	N/A	0.29	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Brookfield Corporation BN

$90.5B

Apollo Global Mgmt Inc APO

$64.4B

Kkr & Co Inc KKR

$82.5B

Ares Management Corporation ARES

$24.5B

Blackrock BLK

$149.6B

Frequently Asked Questions

What is Brookfield Asst's annual revenue?

Brookfield Asst (BAM) reported $4.8B in total revenue for fiscal year 2025. This represents a 21.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Brookfield Asst's revenue growing?

Brookfield Asst (BAM) revenue grew by 21% year-over-year, from $4.0B to $4.8B in fiscal year 2025.

Is Brookfield Asst profitable?

Yes, Brookfield Asst (BAM) reported a net income of $2.4B in fiscal year 2025, with a net profit margin of 49.8%.

What is Brookfield Asst's net profit margin?

Brookfield Asst (BAM) had a net profit margin of 49.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Brookfield Asst's return on equity (ROE)?

Brookfield Asst (BAM) has a return on equity of 26.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Brookfield Asst's operating cash flow?

Brookfield Asst (BAM) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Brookfield Asst's total assets?

Brookfield Asst (BAM) had $17.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Does Brookfield Asst buy back shares?

Yes, Brookfield Asst (BAM) spent $412.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Brookfield Asst's debt-to-equity ratio?

Brookfield Asst (BAM) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Brookfield Asst's return on assets (ROA)?

Brookfield Asst (BAM) had a return on assets of 14.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Brookfield Asst's Piotroski F-Score?

Brookfield Asst (BAM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Brookfield Asst's earnings high quality?

Brookfield Asst (BAM) has an earnings quality ratio of 0.88x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.